A meta-analysis on 20 studies bodes well for cocoa flavanol intake.
A Cochrane Review on cocoa flavanols has concluded that high consumption of these compounds can significantly reduce blood pressure.
Researchers from the University of Adelaide and the National Institute of Integrative Medicine in Melbourne conducted a meta-analysis on 20 clinical trials involving over 800 adults (with or without hypertension) who consumed cocoa flavanols or a control for 2 to 18 weeks. Changes in systolic and diastolic blood pressure were investigated in each study.
In compiling all of the data, statistically significant reductions were observed with flavanol-rich cocoa consumption for both diastolic (-2.2 mm Hg) and systolic blood pressure (-2.8 mm Hg) compared to consumption of zero flavanols.
But how high of a dose is needed for efficacy?
The researchers couldn’t reach a consensus on how many flavanols might cause blood pressure changes because the studies used a wide range of flavanols (from 30 mg to 1080 mg daily). The average amount used was 545.5 mg of flavanols daily.
While a meta-analysis on 20 studies provides a strong case for cocoa-rich foods in overall nutrition, the researchers noted that more work is needed to iron out a definitive opinion of how exactly cocoa flavanols can support healthy blood pressure for the general population:
More trials in which the intake of low flavanol dosages are compared with flavanol-free controls are required to test whether low dosages are effective in reducing blood pressure. In addition, longer term trials are needed to elucidate whether regular consumption of flavanol-rich cocoa products has a beneficial effect on blood pressure and cardiovascular health over time, and whether there are any potential adverse effects of long-term ingestion of cocoa products on a daily basis.
Meta-analysis does not find increased risk of bleeding events from omega-3 PUFA consumption
July 8th 2024Researchers reviewed 11 studies and found that there was no difference in the incidence of bleeding events between patients receiving omega-3 PUFAs and those not receiving them. High dose EPA consumption was associated with an elevated but modest risk.
Recent review states that pentadecanoic acid may support cellular stability for better longevity
June 25th 2024According to the paper’s author, Stephanie Venn-Watson, DVM, MPH, deficiency in pentadecanoic acid of ≤0.2% total circulating fatty acids increases the risk of ferroptosis, which a type of cell death cause by the peroxidation of fragile fatty acids in cell membranes that combines with iron thus increasing reactive oxygen species, and disabling mitochondria.
Recent review makes the case for testing omega-3 fatty acid levels in humans
May 23rd 2024The article commissioned by The Global Organization for EPA and DHA Omega-3s (GOED) reviewed the state of omega-3 fatty acid testing, highlighting the value of testing and the commercially available options for diagnostic testing.
Epax launches concentrated oil that combines omegas 3, 9, and 11
May 10th 2024The blend of long-chain polyunsaturated fatty acids and long-chain monounsaturated fatty acids combines the heart and brain health benefits of omegas-3s with the skin and metabolic health benefits of omegas 9 and 11.